4/A: 180 Life Sciences Director Amends Ownership Filing, Details Equity and Option Awards

Stephen H. Shoemaker, a Director of 180 Life Sciences Corp., filed an amended Form 4 detailing the acquisition of 67,439 restricted common shares and 165,000 non-qualified stock options as compensation for board service.

Summary

• Stephen H. Shoemaker, a Director of 180 Life Sciences Corp., filed an amended Form 4 to report changes in his beneficial ownership.
• On June 17, 2025, Shoemaker acquired 67,439 shares of common stock. These are restricted shares vesting 50% on December 17, 2025, and 50% on June 17, 2026, contingent on his continued service. These shares were issued under the Issuer's 2022 Equity Compensation Plan.
• Also on June 17, 2025, he acquired 165,000 non-qualified stock options with an exercise price of $0.929. These options vest 50% on December 17, 2025, and 50% on June 17, 2026, subject to continued service, and expire on June 17, 2035.
• Both the shares and options were issued as compensation for services rendered and agreed to be rendered as a member of the Board of Directors, with an acquisition price of $0.0.
• The Form 4/A was filed because the number of shares awarded was retroactively adjusted by the Board and Compensation Committee on June 28, 2025, to ensure compliance with the Equity Plan's capacity for this and other awards.
• The 165,000 options were issued under the 2025 Option Incentive Plan, which requires stockholder approval; options cannot be exercised until approval is obtained and will be cancelled if approval is not granted.
• Following these transactions, Shoemaker beneficially owns 132,439 direct common shares and 165,000 direct non-qualified stock options.

Sentiment

Score: 5

Explanation: Neutral. The filing is a routine insider transaction disclosure. While the equity awards are positive for aligning interests, the retroactive adjustment and the contingency of options on shareholder approval introduce minor administrative and governance concerns, balancing the overall sentiment.

Positives

• Issuance of equity and options to a director aligns his interests with shareholders, incentivizing long-term commitment and performance.
• The company is utilizing its equity compensation plans (2022 Equity Compensation Plan and proposed 2025 Option Incentive Plan) to attract and retain board talent.

Negatives

• The retroactive adjustment of share awards suggests potential administrative oversight or capacity issues with the Equity Plan, requiring a corrective amendment.
• The 2025 Option Incentive Plan, under which 165,000 options were granted, is subject to stockholder approval, introducing uncertainty regarding the validity and exercisability of these options. If approval is not obtained, the options will be cancelled.

Risks

• Risk of cancellation of 165,000 stock options if the 2025 Option Incentive Plan does not receive stockholder approval.
• Potential for negative perception or scrutiny due to the need for a retroactive adjustment of equity awards, indicating possible initial miscalculation or insufficient planning regarding the Equity Plan's capacity.

Future Outlook

The future exercisability of the 165,000 stock options is contingent upon stockholder approval of the 2025 Option Incentive Plan. The vesting of both the restricted shares and options is tied to the director's continued service through June 17, 2026.

Management Comments

• Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan.
• Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.
• The options vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2025 Option Incentive Plan. The 2025 Option Incentive Plan is subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for such plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained.
• This Form 4/A is being filed to reflect the fact that the number of shares awarded to the Reporting Person was retroactively adjusted by the Board of Directors and Compensation Committee of the Company on June 28, 2025, so that there was sufficient room for such award, and other awards made on the same date, under the Equity Plan.

Industry Context

This filing is a standard disclosure of insider transactions, common across all publicly traded companies. It reflects a company's use of equity-based compensation to align director incentives with shareholder value, a prevalent practice in the life sciences and broader corporate sectors. The need for a retroactive adjustment, however, could indicate internal administrative challenges, which are less common but not unheard of in smaller or rapidly evolving companies.

Comparison to Industry Standards

• The use of restricted stock and stock options as director compensation is a standard practice in the life sciences industry, similar to companies like Moderna or Pfizer, which also use equity to incentivize leadership.
• The vesting schedule (50% in 6 months, 50% in 12 months) is a common approach to ensure continued service, comparable to typical executive compensation packages seen at biotech firms.
• The requirement for stockholder approval for a new option plan (2025 Option Incentive Plan) is a standard corporate governance practice, ensuring shareholder oversight of dilution and compensation.
• The retroactive adjustment of awards due to insufficient room under an existing equity plan is less common and could be viewed as an administrative anomaly compared to larger, more established companies with robust compensation governance.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution from new equity awards, but also alignment of director interests with long-term company performance. Uncertainty regarding the 2025 Option Incentive Plan approval.
• Employees: Not directly impacted by this specific director compensation, but the overall equity compensation plans affect all participants.
• Management/Board: Stephen H. Shoemaker's compensation package is detailed, incentivizing his continued service. The Board and Compensation Committee demonstrated oversight by correcting the award size.

Next Steps

• Stockholder approval for the 2025 Option Incentive Plan is required for the 165,000 options to become exercisable.
• Vesting of restricted shares and options will occur on December 17, 2025, and June 17, 2026, subject to continued service.

Key Dates

Recommendation

Keywords

180 Life Sciences Corp., ATNF, Form 4/A, SEC filing, beneficial ownership, Stephen H. Shoemaker, director compensation, equity awards, stock options, restricted stock, vesting, corporate governance, insider transaction, compensation plan, stockholder approval